IOL Chemicals and Pharmaceuticals Limited conducted a business update conference call on 11th September 2026 to discuss three strategic growth initiatives involving a total investment of approximately INR500 crore. The call was moderated by MUFG Investor Relations and featured management representatives including Mr. Abhay Raj Singh (Sr. Vice President & Company Secretary), Mr. Pardeep Kumar Khanna (CFO), Mr. Kushal Kumar Rana (Director Works), and Mr. Rakesh Mahajan (Finance Advisor and Strategic Head).

Strategic Initiatives Overview

The company announced three key growth projects:

1. Ibuprofen API Capacity Expansion

  • Expansion of Ibuprofen capacity by 6,000 MTPA, taking total capacity to 18,000 MTPA
  • Investment of approximately INR350 crore
  • Fully backward integrated facility
  • Expected commissioning by December 2027
  • Existing facilities operating at 90-95% utilization
  • Expected revenue multiple of 1.75x-2x of investment at peak utilization
  • Targeted utilization: 25% in FY28, optimal utilization (>80%) expected in FY28-29

2. CDMO Formulations Facility

  • New CDMO facility with capacity of 1,500 million tablets per annum or equivalent Direct Compressible Grade volume
  • Investment of approximately INR110 crore
  • Received EU GMP certification
  • Targeting commercialization in Q3 FY27 (December 2026 quarter)
  • Expected revenue multiple of 1x-1.25x at 90% utilization
  • Optimal utilization expected in 18-24 months after commercialization
  • Contracts typically 3-5 years with escalation clauses
  • Margins expected to be better than API business

3. Specialty Chemicals Tolling Facility

  • Dedicated specialty chemical facility under long-term tolling arrangement
  • Customer-led investment with identified global chemical company
  • Provides visibility of long-term manufacturing demand

Financial Details

  • Total investment: INR500 crore across three initiatives
  • 30% of funding requirements already incurred
  • Remaining capex to be funded through internal accruals
  • Investments expected to contribute 25-30% incremental revenue to top line at peak utilization
  • Expected ROCE: approximately 15% when all projects are fully implemented
  • Capex timeline: Spread across FY27 and FY28

Market Context and Strategy

  • Ibuprofen global growth rate: 3-4% annually
  • Expansion driven by customer requirements and market opportunities, not specific competitor shutdowns
  • CDMO business initiated based on customer requests for bulk tablets instead of APIs
  • Backward integration provides raw material price fluctuation control
  • Contracts include price adjustment clauses for raw material price changes

Current Business Environment

  • Paracetamol prices have softened from peak levels
  • Ibuprofen prices remain stable around current levels
  • Raw material price impacts from geopolitical events have been neutralized
  • Company maintains guidance of 15-20% growth

Additional Projects

  • Greenfield project at new land (100 acres) is separate from these announcements
  • Regulatory approvals process ongoing for greenfield project
  • Initial base work started but complete work pending all approvals

Management Commentary

Management emphasized that these initiatives are part of the company's long-term strategy focused on:

  • Strengthening core businesses
  • Accelerating diversification
  • Pursuing customer-led opportunities
  • Maintaining disciplined capital allocation
  • Leveraging backward integration capabilities

The company expects to continue regular capacity enhancements and new product introductions based on market response and future possibilities.